4.6 Article

Lymph Node Dissection Technique Is More Important Than Lymph Node Count in Identifying Nodal Metastases in Radical Cystectomy Patients: A Comparative Mapping Study

Journal

EUROPEAN UROLOGY
Volume 60, Issue 5, Pages 946-952

Publisher

ELSEVIER
DOI: 10.1016/j.eururo.2011.07.012

Keywords

Cystectomy; Extended lymphadenectomy; Bladder cancer; Metastases

Ask authors/readers for more resources

Background: The value of lymph node dissection (LND) in the treatment of bladder urothelial carcinoma is well established. However, standards for the quality of LND remain controversial. Objective: We compared the distribution of lymph node (LN) metastases in a two-institution cohort of patients undergoing radical cystectomy (RC) using a uniformly applied extended LND template. Design, setting, and participants: Patients undergoing RC at the University of Southern California (USC) Institute of Urology and at Oregon Health Sciences University (OHSU) were included if they met the following criteria: (1) no prior pelvic radiotherapy or LND; (2) lymphatic tissue submitted from all nine predesignated regions, including the paracaval and para-aortic LNs; (3) bladder primary; and (4) category M0 disease. The number and location of LN metastases were prospectively entered into corresponding databases. Measurements: LN maps were constructed and correlated with preoperative and pathologic characteristics. Kaplan-Meier curves were constructed to estimate overall survival (OS) and recurrence free survival (RFS) among LN-positive (LN+) patients. Results and limitations: Inclusion criteria were met by 646 patients (439 USC, 207 OHSU), and 23% had LN metastases at time of cystectomy. Although there was a difference in the median per-patient LN count between institutions, there were no significant interinstitutional differences in the incidence or distribution of positive LNs, which were found in 11% of patients with <= pT2b and in 44% of patients with >= pT3a tumors. Among LN+ patients, 41% had positive LNs above the common iliac bifurcation. Estimated 5-yr RFS and OS rates for LN+ patients were 45% and 33%, respectively, and did not differ significantly between institutions. Conclusions: LN metastases in regions outside the boundaries of standard LND are common. Adherence to meticulous dissection technique within an extended template is likely more important than total LN count for achieving optimal oncologic outcomes. (C) 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature

Leslie Ballas, Oren Wei, Siamak Daneshmand, Anne Schuckman, Hooman Djaladat, Monish Aron, Anishka D'Souza, David Quinn, Tanya B. Dorff

CLINICAL GENITOURINARY CANCER (2020)

Article Urology & Nephrology

Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer

Yair Lotan, Iftach Chaplin, Hamed Ahmadi, Xiaosong Meng, Sidney Roberts, Sanam Ladi-Seyedian, Aditya Bagrodia, Vitaly Margulis, Solomon Woldu, Siamak Daneshmand

Summary: The study evaluated the utility of blue-light flexible cystoscopy (BLFC) for surveillance of non-muscle-invasive bladder cancer (NMIBC). Results showed that incorporating BLFC in clinical practice has the potential advantages of detecting cancer in cases with normal WLC and detecting additional cancers in patients with positive WLC and BLFC, which can improve surveillance and performance of office-based biopsy. Further research is needed to determine cost-effectiveness and impact on recurrence rates.

BJU INTERNATIONAL (2021)

Article Urology & Nephrology

Machine Learning to Delineate Surgeon and Clinical Factors That Anticipate Positive Surgical Margins After Robot-Assisted Radical Prostatectomy

Ryan S. Lee, Runzhuo Ma, Stephanie Pham, Jacqueline Maya-Silva, Jessica H. Nguyen, Manju Aron, Steven Cen, Siamak Daneshmand, Andrew J. Hung

Summary: This study utilized machine learning to investigate the predictive ability of surgeon performance and clinical factors on positive surgical margins (PSMs) after robot-assisted radical prostatectomy (RARP). The strongest predictors of PSMs were found to be nonmodifiable, disease-driven factors (ECE and pT), with automated performance metrics (APMs) also capable of independently predicting PSMs.

JOURNAL OF ENDOUROLOGY (2022)

Article Oncology

Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients

Charles Nguyen, Saum Ghodoussipour, Matthew Winter, Giovanni Cacciamani, Hamed Ahmadi, Hooman Djaladat, Anne K. Schuckman, Siamak Daneshmand, Monish Aron, Inderbir Gill, Mihir Desai

Summary: This study aimed to assess the impact of chronic kidney disease (CKD) on outcomes in bladder cancer patients undergoing radical cystectomy. The results showed that CKD was independently associated with adverse pathology, 90-day readmissions, and transfusion.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Oncology

The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial

Siamak Daneshmand, Iris S. G. Brummelhuis, Kamal S. Pohar, Gary D. Steinberg, Manju Aron, Christopher J. Cutie, Kirk A. Keegan, John C. Maffeo, Donald L. Reynolds, Bradley Raybold, Albert Chau, J. Alfred Witjes

Summary: TAR-200 is a safe and well-tolerated treatment for MIBC patients undergoing radical cystectomy.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Oncology

Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics

Frederik Konig, Nico C. Grossmann, Francesco Soria, David D'Andrea, Tristan Juvet, Aaron Potretzke, Hooman Djaladat, Alireza Ghoreifi, Eiji Kikuchi, Nozomi Hayakawa, Andrea Mari, Zine-Eddine Khene, Kazutoshi Fujita, Jay D. Raman, Alberto Breda, Matteo Fontana, John P. Sfakianos, John L. Pfail, Ekaterina Laukhtina, Pawel Rajwa, Maximilian Pallauf, Giovanni E. Cacciamani, Thomas van Doeveren, Joost L. Boormans, Alessandro Antonelli, Marcus Jamil, Firas Abdollah, Jeffrey Budzyn, Guillaume Ploussard, Axel Heidenreich, Siamak Daneshmand, Stephen A. Boorjian, Morgan Roupret, Michael Rink, Shahrokh F. Shariat, Benjamin Pradere

Summary: Measuring the quality of care is important in improving patient outcomes. In this study, five indicators were identified to assess the quality of care for patients with upper urinary tract cancer who undergo surgical removal of the affected kidney and ureter. Patients who achieved all five indicators had higher chances of survival and lower rates of recurrence. There were no patient-related factors that predicted a failure to achieve these indicators.

CANCERS (2022)

Article Oncology

Impact of Patient, Surgical, and Perioperative Factors on Discharge Disposition after Radical Cystectomy

Giovanni E. Cacciamani, Ryan S. Lee, Daniel Sanford, Wesley Yip, Jie Cai, Gus Miranda, Siamak Daneshmand, Monish Aron, Hooman Djaladat, Inderbir S. Gill, Mihir Desai

Summary: This study evaluated the impact of patient and surgical factors on discharge disposition after radical cystectomy for bladder cancer. It found that older age, living alone prior to surgery, and/or major post-operative complications were significant predictors of discharge to rehabilitation facilities.

CANCERS (2022)

Editorial Material Oncology

Plasma Micro-RNA 371 Expression in Early-Stage Germ Cell Tumors: Are We Ready to Move Toward Biology-Based Decision Making?

Muhannad Alsyouf, Lucia Nappi, Craig Nichols, Siamak Daneshmand

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy

Siamak Daneshmand, Clint Cary, Timothy Masterson, Lawrence Einhorn, Nabil Adra, Stephen A. Boorjian, Christian Kollmannsberger, Anne Schuckman, Alan So, Peter Black, Aditya Bagrodia, Eila Skinner, Mehrdad Alemozaffar, Timothy Brand, Scott Eggener, Phillip Pierorazio, Kelly Stratton, Lucia Nappi, Craig Nichols, Chunqiao Luo, Ming Li, Brian Hu

Summary: This study aimed to investigate the efficacy of RPLND as a first-line treatment for testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy. The results showed that the 2-year recurrence-free survival rate was 81%, the recurrence rate was 22%, and the 2-year overall survival rate was 100%. The study concluded that RPLND is a viable treatment option with low long-term morbidity.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma

Daniel D. Joyce, Vidit Sharma, Kevin M. Wymer, James P. Moriarty, Bijan J. Borah, Arman Walia, Brian A. Costello, Lance C. Pagliaro, Siamak Daneshmand, Bradley C. Leibovich, Stephen A. Boorjian

Summary: This study evaluated the cost-effectiveness of three treatment strategies for stage IIA seminoma and found that retroperitoneal lymph node dissection was the most cost-effective approach, followed by radiotherapy, and chemotherapy had the lowest cost-effectiveness. These findings support considering retroperitoneal lymph node dissection as a treatment option for well-selected patients with stage IIA seminoma in clinical guidelines.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Review Oncology

The Impact of Dose Reduction of Bacillus Calmette-Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Wadi Azuri, Jorge Horacio Jaunarena, Juan Jorge Camean, Joaquin Chemi, Alberto Villaronga, Siamak Daneshmand, Gustavo Martin Villoldo

Summary: This study evaluated the impact of BCG dose reduction on oncological outcomes and toxicity in patients with nonmuscle invasive bladder cancer. The results showed that dose reduction did not affect oncological outcomes, but significantly reduced systemic and local toxicity.

BLADDER CANCER (2023)

Review Urology & Nephrology

Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence

Siamak Daneshmand, Azadeh Nazemi

EUROPEAN UROLOGY FOCUS (2020)

Review Oncology

Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours

Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, Joan Palou, John A. Taylor, James McKiernan, James Catto, Marko Babjuk, Mark Soloway

Summary: TURBT is a common but challenging urological procedure with variable outcomes. The review identified optimal best practices for TURBT, including preparation, procedural steps, surgical techniques, and postoperative management. Development of new instruments and techniques, as well as prospective audit of TURBT outcomes, are important future goals.

EUROPEAN UROLOGY ONCOLOGY (2021)

No Data Available